Stepping up the game: scale up and international expansion for British AI medical software

加速游戏：英国人工智能医疗软件的规模化和国际扩张

• 批准号: 10057456
• 金额: $ 6.37万
• 依托单位: OXFORD HEARTBEAT LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10057456
• 关键词: Stepping; up; game; scale; international

I am a CEO of Oxford Heartbeat (OxHB) - mission-driven medical technology startup. I am also an Enterprise Fellow of The Royal Academy of Engineering, a PhD in Biomedical Engineering from University of Oxford, MSc in Computer Science from Humboldt University of Berlin (minor in Business) and was previously Researcher in AI at Sony in Paris. I was named a "founder striving to change the world" by Forbes and recently awarded the BioMedEng Innovation Prize for "imaginative and ground breaking work that led to new technologies supporting medical interventions."After obtaining a PhD and having witnessed the shortcomings of the status quo in surgery, I founded OxHB to translate my academic research to clinical practice. I am both CEO and CTO of the company, which has developed innovative AI software PreSize Neurovascular allowing surgeons to simulate placement of stent implants within blood vessels so they can more safely and effectively treat cardiovascular diseases, defining a new standard of surgical planning.We have achieved CE-marking and ISO13485-certification and are now running a UK-wide clinical trial to collect evidence of its impact in clinical practice, funded by the UK Government's prestigious AI in Health and Care Award and NIHR.The Women In Innovation Award will support our preparations for scale up and internationalisation - the critical next step to grow our business and become global players.The award's non-financial support, i.e., expert advice on scaling up, sales and negotiations skills and building new business models, will contribute to our timely preparation for expansion of our business globally, thus helping OxHB enter a new stage of its journey.Success of this project would be seeing our efforts, supported by this award, flourishing into commercial engagements, and importantly, benefitting many patients' lives.Results from our previous projects received numerous awards, including NHS Innovation Award 2017 (HEE), WIRED "Best UK Healthcare Start-up of 2018", and our PreSize technology has been recently featured in The Times (6 September 2021).

我是Oxford Heartbeat（OxHB）的首席执行官，这是一家以使命为导向的医疗技术初创公司。我还是皇家工程学院的企业研究员，牛津大学生物医学工程博士，柏林洪堡大学计算机科学硕士（辅修商业），之前曾在巴黎的索尼公司担任人工智能研究员。我被《福布斯》评为“努力改变世界的创始人”，最近还被授予"生物医学工程创新奖“，以表彰我“富有想象力和开创性的工作，这些工作导致了支持医疗干预的新技术”。“在获得博士学位并目睹了手术现状的缺点后，我创立了OxHB，将我的学术研究转化为临床实践。我是该公司的首席执行官和首席技术官，该公司开发了创新的人工智能软件PreSize Neurovascular，允许外科医生模拟血管内支架植入物的放置，以便更安全有效地治疗心血管疾病，定义了手术计划的新标准。我们已获得CE标志和ISO 13485认证，目前正在运行一个英国-广泛的临床试验，以收集其在临床实践中的影响的证据，由英国政府著名的AI健康与护理奖和NIHR资助。女性创新奖将支持我们为扩大规模和国际化做准备-这是我们发展业务并成为全球参与者的关键下一步。该奖项的非财务支持，即，在扩大规模、销售和谈判技巧以及建立新的商业模式方面提供专家建议，将有助于我们及时为全球业务扩张做好准备，从而帮助OxHB进入新的旅程阶段。该项目的成功将见证我们的努力，在这个奖项的支持下，蓬勃发展成为商业活动，更重要的是，使许多患者受益。我们以前的项目成果获得了众多奖项，包括2017年NHS创新奖（HEE）、WIRED“2018年英国最佳医疗保健初创企业”，而我们的PreSize技术最近在《泰晤士报》（2021年9月6日）上有报道。